| Name: | Bortezomib Impurity 20 |
| Catalogue No. | VE007401 |
| CAS No. | 89618-77-9 |
| Molecular Formula | C14H24BClO2 |
| Molecular Weight | 270.61 g/mol |
| Status | In-Stock |
| IUPAC Name | (3aS,4S,6S,7aR)-2-((S)-1-chloro-2-methylpropyl)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole |
| Description | Bortezomib Impurity 20 (CAS No: 89618-77-9) or (3aS,4S,6S,7aR)-2-((S)-1-chloro-2-methylpropyl)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborole is associate impurity of Bortezomib. Bortezomib is employed to treat people with multiple myeloma (a type of cancer of the bone marrow). ortezomib is during a category of medicines known as antineoplastic agents. |
| References | “Sci-Hub | Analysis of Two Commercially Available Bortezomib Products: Differences in Assay of Active Agent and Impurity Profile | 10.1208/S12249-010-9554-1.” Hkvisa.net, 2022, sci-hub.hkvisa.net/10.1208/s12249-010-9554-1. |
